Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sunrun Inc (RUN) vs Zoetis Inc (ZTS) Price & Performance

Sunrun IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Sunrun Inc vs Zoetis Inc — how do they compare? Sunrun Inc trades at $8.84 (market cap $2.22B), while Zoetis Inc trades at $73.7 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 13.7× Sunrun Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.

RUNZTS
Market Cap
$2.22B$30.40B
Sector
TechnologyHealth
52-Week High
$21.41$150.61
52-Week Low
$8.37$71.91
Enterprise Value
$16.74B$37.96B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sunrun Inc

Sunrun (RUN) trades at $9.22, up 3.71% today, but faces a bearish technical trend with resistance at $10. The company shows mixed fundamentals: it beat Q2 2026 EPS estimates ($0.42 actual vs. $0.23 expected) but cut full-year guidance, contributing to a 46% stock decline. Revenue is projected to grow to $3.5B in 2026, yet net income margin may drop to 11.59%. Recent news highlights a partnership with Voltus for AI hyperscaler energy capacity, offering a potential growth catalyst amid operational challenges.

The outlook is cautious; RUN appears undervalued with a P/E of 6.27 and P/B of 0.64, but risks include weak cash flow from operations (-$421M in 2025) and high debt. Analyst consensus is bullish (62% buy ratings) with a $14.70 price target, implying 59% upside, though execution on subscriber growth and margin recovery is critical for realizing gains.

Zoetis Inc

Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.

The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sunrun Inc

Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.

Read more on RUN

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS